A structural characterization was not performed, whereas the biological analysis revealed that the heterodetic cyclic peptide (VEGF-P3CYC) inhibits VEGFR-2 activity and blocks tumor growth in vivo. The gene discussed is VEGFA; the disease is neoplasm.